Literature DB >> 28647355

Random-start ovarian stimulation in women desiring elective cryopreservation of oocytes.

Nigel Pereira1, Anna Voskuilen-Gonzalez2, Kolbe Hancock3, Jovana P Lekovich2, Glenn L Schattman2, Zev Rosenwaks2.   

Abstract

The current study investigates the utility of random-start ovarian stimulation in women desiring elective oocyte cryopreservation. Women in the study cohort underwent random-start ovarian stimulation, and were subdivided based on the phase of the menstrual cycle that ovarian stimulation began, i.e. early follicular, late follicular or luteal phase. Women undergoing conventional cycle day (CD) 2/3 ovarian stimulation start were controls. A total of 1302 women were included - 859 (66.0%) conventional CD 2/3, 342 (26.3%) early follicular, 42 (3.2%) late follicular and 59 (4.5%) luteal ovarian stimulation starts. There was no difference in the demographics or baseline ovarian stimulation characteristics. The duration of ovarian stimulation (11 versus 9 days; P < 0.001) and total dosage of gonadotrophins administered (4095.5 versus 3155 IU; P < 0.001) was higher in the random-start group. The number of total and MII oocytes in the control and random-start groups was similar. A non-significant trend towards increased cycle cancellation was noted in the late follicular start group (7.1%). Study findings indicate the number of total and MII oocytes derived from random-start protocols initiated during any phase of the menstrual cycle is similar to conventional CD 2/3 ovarian stimulation start protocols in women desiring elective oocyte cryopreservation.
Copyright © 2017 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  elective oocyte cryopreservation; oocyte cryopreservation; ovarian stimulation; random-start; social oocyte cryopreservation

Mesh:

Year:  2017        PMID: 28647355     DOI: 10.1016/j.rbmo.2017.06.002

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  6 in total

1.  Is letrozole during ovarian stimulation useful in breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist trigger?

Authors:  Imane Lalami; Julie Labrosse; Isabelle Cedrin-Durnerin; Marjorie Comtet; Claire Vinolas; Fabien Krief; Christophe Sifer; Maeliss Peigne; Michael Grynberg
Journal:  Reprod Biol Endocrinol       Date:  2022-06-11       Impact factor: 4.982

Review 2.  ART outcomes following ovarian stimulation in the luteal phase:a systematic review and meta-analysis.

Authors:  Buo-Jia Lu; Chien-Ju Lin; Bou-Zenn Lin; Li Huang; Li-Ting Chien; Chi-Huang Chen
Journal:  J Assist Reprod Genet       Date:  2021-05-25       Impact factor: 3.357

3.  Random-start ovarian stimulation with aromatase inhibitor for fertility preservation in women with Japanese breast cancer.

Authors:  Takashi Nakasuji; Kiyotaka Kawai; Tomonori Ishikawa; Kaori Teraoka; Shiho Takeuchi; Tomoko Miyagawa; Kazuko Nara; Nobuyuki Kidera; Tatsuya Harada; Naoyuki Miyasaka
Journal:  Reprod Med Biol       Date:  2019-01-02

4.  Oocyte cryopreservation for future fertility: comparison of ovarian response between cancer and non-cancer patients.

Authors:  Camila Cruz de Moraes; Victoria Furquim Werneck Marinho; Ana Luísa Menezes Campos; Janaína de Souza Guedes; Érica Becker de Sousa Xavier; João Pedro Junqueira Caetano; Ricardo Mello Marinho
Journal:  JBRA Assist Reprod       Date:  2019-04-30

5.  ESHRE guideline: ovarian stimulation for IVF/ICSI.

Authors:  The Eshre Guideline Group On Ovarian Stimulation; Ernesto Bosch; Simone Broer; Georg Griesinger; Michael Grynberg; Peter Humaidan; Estratios Kolibianakis; Michal Kunicki; Antonio La Marca; George Lainas; Nathalie Le Clef; Nathalie Massin; Sebastiaan Mastenbroek; Nikolaos Polyzos; Sesh Kamal Sunkara; Tanya Timeva; Mira Töyli; Janos Urbancsek; Nathalie Vermeulen; Frank Broekmans
Journal:  Hum Reprod Open       Date:  2020-05-01

Review 6.  The Future of Cryopreservation in Assisted Reproductive Technologies.

Authors:  Ernesto Bosch; Michel De Vos; Peter Humaidan
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-20       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.